Albemarle's Q2 2026 sales rose 31% to $1.74 billion and adjusted EBITDA 155% to $858 million, but the revenue bridge shows price added $562 million while volume added only $28 million — a lithium-index recovery on top of a balance sheet cut from $3.1 billion to $1.8 billion of long-term debt.
Lithium prices did the work: adjusted EBITDA up 155%, with price adding $562 million of sales and volume only $28 million
Albemarle's second quarter of 2026 (the three months to June 30, filed on Form 10-Q on August 5, 2026) is the quarter the lithium downcycle stopped setting the terms. Net sales rose 31% to $1.743 billion and net income attributable to Albemarle reached $480.0 million, against $22.9 million a year earlier — a quarter that had actually left common shareholders with a small loss once preferred dividends were deducted.
The mechanism is narrow and worth stating precisely. Management's own revenue bridge attributes $561.8 million of the $413.3 million sales increase to higher pricing, with only $28.4 million from volume (nearly all of it in Specialties) and $38.5 million from a weaker US dollar, offset by a $215.3 million hole left by the Refining Solutions business sold on March 2, 2026. In other words, price added more than the entire reported increase; everything else netted negative. Albemarle sells most of its lithium salts on index-referenced, variable-priced contracts — the price is reset off published market benchmarks rather than fixed in advance — so when the lithium index moves, revenue moves with it in the same quarter.
Metric
Q2 2026
Q2 2025
YoY change
Net sales
$1,743.3M
$1,330.0M
+31%
Gross margin
33.9%
14.8%
+19.1 pts
Operating profit
$452.9M
$47.5M
Read 0 community reports on Albemarle Corporation, or write your own.Write a report
Two terms carry most of the weight above. Adjusted EBITDA is Albemarle's preferred profit measure: earnings before interest, tax, depreciation and amortisation, further adjusted for items management treats as one-off (restructuring, business-sale losses, and — unusually — its 49% share of the tax paid by its Windfield mining joint venture). It is the metric written into the company's credit-agreement leverage covenant, which is why it gets top billing. LCE means lithium carbonate equivalent, a common unit that lets lithium sold in different chemical forms — carbonate, hydroxide, or raw spodumene rock concentrate — be added up and priced on one scale. Albemarle's realised price of $19.53 per kilogram LCE is what it actually received; the "market price" scenarios further down are index averages.
Energy Storage: price up 60%, volume up 11%, and a fire at the mine
Energy Storage sales rose 78% to $1.277 billion, of which $522.5 million came from "favorable pricing impacts, primarily in battery- and technical-grade carbonate and hydroxide sold under index-referenced and variable-priced contracts." Volume contributed just $2.0 million, as higher customer demand was "partially offset by unfavorable product mix and reduced tolling volumes" — tolling being third-party conversion work Albemarle does for a fee, which carries revenue but little of the price leverage.
Segment adjusted EBITDA more than tripled to $723.5 million. Three effects deserve separating out:
A cheap-inventory tailwind that is finite. Gross margin more than doubled to 33.9%, and the first driver management lists is "lower average input costs, driven by the consumption of lower-priced raw material inventory in Energy Storage." That inventory was bought when spodumene was cheap. It is being replaced at today's prices: purchases from unconsolidated affiliates ran $322.5 million in the quarter versus $158.6 million a year ago, inventories on the balance sheet rose to $1.385 billion from $1.179 billion at year-end, and amounts owed to related parties jumped to $445.4 million from $134.4 million. The margin benefit is a timing lag, not a structural cost improvement.
A quarter of the profit sits inside a joint venture. Equity in net income of unconsolidated investments — Albemarle's share of profits from businesses it part-owns but does not consolidate — rose 94% to $151.6 million, "primarily due to higher pricing realized by the Windfield joint venture." Add back the $70.8 million of Windfield tax that the adjusted EBITDA definition excludes, and roughly $222 million, or 26%, of the $858.1 million headline figure is pre-tax joint-venture earnings rather than profit from operations Albemarle controls. That cash only reaches the parent as dividends, and the timing of one such dividend is exactly what management credits for the quarter's cash generation.
Costs that rise with price. Adjusted EBITDA growth was held back by "increased commission expenses in Chile resulting from the higher pricing" — the CORFO royalty on Chilean lithium scales with realised price, so part of every price gain is paid away.
The operational negative is a June 9 fire at the third chemical grade plant (CGP3) at the Talison joint venture's Greenbushes mine in Western Australia. Management now expects "minimal impact" to full-year Energy Storage volumes, because output from the Wodgina mine ran better than planned and inventory was run leaner; remediation and the ramp back to normal production are expected to finish in the second half of 2026. Full-year sales volumes are guided to 225–235 kilotons LCE.
Specialties: the only segment where volume is actually growing
Specialties — bromine-based flame retardants, lithium specialties, and materials for semiconductors and pharmaceuticals — grew sales 20.5% to $423.5 million on both price (+11%) and volume (+8%), with $38.5 million of the gain from "favorable pricing impacts in bromine and derivatives and flame retardants, partially offset by unfavorable pricing in lithium specialties" and $29.7 million from higher volumes, mostly flame retardants. Adjusted EBITDA rose 61% to $117.7 million, restrained by higher raw material input costs.
This is the part of the portfolio not levered to a single index, and it is the only place management raised guidance: the full-year Specialties outlook went from $1.3–1.5 billion of sales and $225–275 million of adjusted EBITDA at the first quarter to $1.4–1.6 billion and $275–325 million now. The offset is geopolitical — the Jordan Bromine Company joint venture continues to operate "despite geopolitical tensions in the region," and the second-half outlook assumes the bromine market stabilises.
The balance sheet is the real change
The Refining Solutions sale and the disposal of the 50% stake in the Eurecat joint venture closed in the first quarter for roughly $648 million of combined pre-tax cash, net of cash sold, and the proceeds went straight into debt. Long-term debt fell to $1.802 billion at June 30 from $3.119 billion at December 31, with $1.314 billion of repayments in the first half; interest and financing expense dropped 38% to $30.9 million for the quarter. Cash stood at $1.632 billion, total liquidity about $3.2 billion, and the credit-agreement net-debt-to-adjusted-EBITDA ratio about 0.5 times.
First-half operating cash flow of $1.056 billion nearly doubled from $538.2 million, and capital spending fell to $170.4 million from $302.3 million. Management flagged the quarter's 83% cash conversion as partly "timing of an increased dividend from the Talison joint venture and non-recurring working capital benefits" — so do not annualise it.
The costs of shrinking are still being paid: $33.2 million of first-half restructuring charges and asset write-offs, with a further $70–90 million of charges expected through 2026 and 2027 from putting Kemerton Train 1 into care and maintenance (Trains 3 and 4 were never finished, Train 2 and the Chengdu conversion plant are also idled, and their production has been shifted to other sites). The Refining Solutions sale itself was booked at a $95.0 million loss, reduced to $52.7 million net of the Eurecat gain.
One share-count point that is easy to miss: the $2.3 billion mandatory convertible preferred stock became dilutive this year, so diluted EPS is calculated on 136.2 million shares rather than the 118.0 million basic count — a 15.5% larger denominator that did not exist in the 2025 comparison, when those shares were excluded as anti-dilutive. The final scheduled preferred dividend is March 1, 2027, after which the $167 million annual dividend stops and the share count is permanently higher.
Takeaway: This is a price recovery, not an operating turnaround. Adjusted EBITDA rose $522 million year over year, and the revenue bridge shows why: price added $562 million of sales against $28 million from volume, while the cost programme has contributed $100 million of run-rate savings for the whole year to date — and roughly a quarter of the headline profit is pre-tax joint-venture income that reaches Albemarle only as dividends. What management actually controlled, and what will matter when the index turns again, is the balance sheet: long-term debt cut from $3.1 billion to $1.8 billion, capex cut to about $500 million, and leverage near 0.5 times.
Outlook: guidance raised only where price is not the driver
Albemarle does not give a single earnings forecast. It publishes scenarios tied to where the lithium index settles for the year, and it left the enterprise version of that table unchanged from the first quarter:
Assumed full-year average lithium market price
~$10/kg LCE (FY2025 average)
~$20/kg LCE (Q1 2026 average)
~$30/kg LCE (2021–25 average)
Total net sales
$4.1–4.3B
$5.7–6.0B
$7.5–7.8B
Total adjusted EBITDA
$0.9–1.0B
$2.4–2.6B
$4.2–4.4B
Energy Storage adjusted EBITDA
$0.7–0.8B
$2.1–2.3B
$3.9–4.1B
Elsewhere, capital spending was cut to approximately $500 million for 2026 (down 15% on 2025, and down from the $550–600 million guided in May), interest and financing expense is put at $120–140 million, depreciation and amortisation at $660–680 million, and the diluted share count at about 136 million. Year-to-date cost and productivity savings of $100 million are tracking to the high end of the $100–150 million full-year target.
The arithmetic in that table is the thing to watch. Albemarle's realised price of $19.53/kg in the second quarter sits almost exactly on the $20 scenario, yet first-half actuals — $3.172 billion of sales and $1.522 billion of adjusted EBITDA — imply only $2.5–2.8 billion of sales and $0.9–1.1 billion of adjusted EBITDA in the second half under that case. Some of that gap is genuine: the cheap-inventory benefit in Energy Storage cost of goods sold is being consumed, Chilean commissions scale up with price, the CGP3 ramp is still incomplete, and the scenarios assume spodumene prices at 10% of the LCE price with all other costs flat. But the scenario table was built in May and not refreshed, while the one piece of segment guidance management did revisit — Specialties — went up. Read the table as a conservative floor for the second half rather than a forecast of deceleration.
The structural question is unchanged by a good quarter: about 40% of salts volume (roughly a third of total volume) sits under long-term agreements, leaving the majority repriced against a volatile index. Albemarle has spent two years converting that exposure from a solvency problem into a cash-flow one — idling conversion capacity, halving debt, cutting capex by 15% — and the second quarter of 2026 is the first in a while where the cycle paid it back. Whether that persists is a question about the lithium index, not about Albemarle's execution.